<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1025">
  <stage>Registered</stage>
  <submitdate>2/05/2001</submitdate>
  <approvaldate>2/05/2001</approvaldate>
  <actrnumber>ACTRN12606000036516</actrnumber>
  <trial_identification>
    <studytitle>A trial to determine if cooling newborn infants at risk of brain damage improves outcome</studytitle>
    <scientifictitle>A randomised controlled trial of the effect of whole body cooling on the outcome of term infants with hypoxic ischaemic encephalopathy (ICE:Infant Cooling Evaluation trial)</scientifictitle>
    <utrn />
    <trialacronym>ICE</trialacronym>
    <secondaryid>Perinatal Trials Registry: PTR367</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Term infants with hypoxic ischaemic encephalopathy</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Children's - Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cooling protocol
This group will have their core temperature lowered to 33.0oC-34.0oC. Temperature will be measured continuously by a thermistor inserted 5 cm into the rectum. Cooling will be started at the birth hospital after the infant has been assessed and stabilised. Cooling will be started and then continued for 72 hours. It will be achieved primarily by turning the radiant warmer off and exposing the infant to ambient temperature. Cool packs around 10oC may then be applied under the neck and across the chest as needed.
Active cooling will be reduced when the rectal temperature falls below 35 oC and stopped when below 34.5oC. The radiant warmer will be on with the skin temperature servo control set at 33.5oC. . 
After 72 hours, re-warming will occur at a rate not exceeding 0.5OC every 2 hours.</interventions>
    <comparator>The normal temperature group
This group will have their rectal temperature maintained between 36.7-37.3oC.</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome is survival free of major sensorineural disability at two years of age. </outcome>
      <timepoint>Surviving infants will be assessed at two years of age by a paediatrician and psychologist blinded to treatment allocation. Major sensorineural disability will comprise cerebral palsy (not walking or unlikely to walk at 2 years), developmental delay (Mental Development Index score of the Bayley Scales of Infant Development &lt;70), blindness (vision &lt;6/60 in both eyes) and deafness requiring hearing aids, as described elsewhere (LD 19).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The primary outcome is survival free of major sensorineural disability at two years of age.
Major sensorineural disability will comprise cerebral palsy (not walking or unlikely to walk at 2 years), developmental delay (Mental Development Index score of the Bayley Scales of Infant Development &lt;70), blindness (vision &lt;6/60 in both eyes) and deafness requiring hearing aids, as described elsewhere (LD 19).</outcome>
      <timepoint>Surviving infants will be assessed at two years of age by a paediatrician and psychologist blinded to treatment allocation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>2.Neurological status</outcome>
      <timepoint>Assessed in the 72 hours after randomisation using the Sarnat classification (Finer modification) and on day 7 of life by the Optimality Score for Neurologic Examination Of Term Newborn. These are measurement tools that can be applied by any neonatologist.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>1.Acute effects during the 72 hours of cooling on: blood pressure, heart rate, haemoglobin, coagulation profile, white cell count, platelets, glucose, sodium, potassium, acid base status and lactate, urine output, respiratory status.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2.Neurological status: by the Optimality Score for Neurologic Examination Of Term Newborn. These are measurement tools that can be applied by any neonatologist.</outcome>
      <timepoint>Assessed in the 72 hours after randomisation using the Sarnat classification (Finer modification) and on day 7 of life.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3.Magnetic Resonance Imaging (MRI) will be done on all infants. A paediatric neuroradiologist blinded to treatment allocation will perform qualitative analysis of the cerebralcortex, basal ganglia and myelination in the posterior limb of the internal capsule.</outcome>
      <timepoint>On day 5-7.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4.Advanced MRI studies including MR spectrospcopy and diffusion MR techniques will also be performed simultaneously with (3) in a subset of infants in those centres that have the facilities. The result will be assessed for its usefulness in predicting adverse outcome and assisting clinical decisions.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1) Infants of 35 weeks gestation or more, 2) Treatment at, or transport to, one of the participating study sites.3) Evidence of moderate or severe encephalopathy:4) Evidence of intrapartum hypoxia: at least two of:    a)Apgar score of 5 or less at 10 minutes;     b)Mechanical ventilation or resuscitation at 10 minutes;     c)Cord pH &lt; 7.00, or an arterial pH &lt; 7.00 or base deficit of 12 or more    within 60 minutes of birth</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Weeks</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1) Cooling cannot be started within 6 hours of birth.2) Birth weight less than 2.0 kg3) Major congenital abnormalities including:   a) Suspected neuromuscular disorders   b) Chromosomal abnormalities   c) Life threatening abnormalities of the cardiovascular or respiratory systems   d) Suspected coagulopathye) Imperforate anus.4) Infants requiring an inspired oxygen over 80%.5) Infant in extremis i.e. very low blood pressure or severe acidosis unresponsive to treatment6) Active cooling has been initiated prior to randomisation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed randomised envelopes are compiled by the CEBU department.</concealment>
    <sequence>Computer generated AND stratified by particpating centre AND blocking</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>8/11/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Murdoch Children's Research Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>RoyalChildren’s Hosp</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Women’s Hosp</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mercy Hosp for Women</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Margaret &amp; King Edward Memorial Hosp</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Hospital for Women</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hosp</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal North Shore Hosp</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Children’s Hosp. at Westmead</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hosp</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>John Hunter Hosp</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hosp</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Canberra Hosp</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Susan Jacobs</name>
      <address>Royal Women's Hospital
132 Grattan St
Carlton VIC 3053</address>
      <phone>+61 3 93443144</phone>
      <fax>+61 3 93442185</fax>
      <email>sue.jacobs@rwh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Susan Jacobs</name>
      <address>Royal Women's Hospital
132 Grattan St
Carlton VIC 3053</address>
      <phone>+61 3 93443144</phone>
      <fax>+61 3 93442185</fax>
      <email>sue.jacobs@rwh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>